ANIX Profile
Anixa Biosciences, Inc., a pioneering biotechnology firm, specializes in developing innovative therapies and vaccines to address significant unmet medical needs in oncology and infectious diseases.
The company’s core focus is on leveraging advanced technologies to create groundbreaking treatments. Anixa's therapeutic pipeline features a chimeric endocrine receptor T-cell therapy, an innovative adaptation of chimeric antigen receptor T-cell (CAR-T) technology designed to target and treat ovarian cancer. This approach aims to enhance the specificity and efficacy of cancer treatments by harnessing the power of the immune system.
In addition to its work in oncology, Anixa is actively developing antiviral drug candidates aimed at treating COVID-19. These candidates focus on inhibiting key protein functions of the virus, potentially offering new therapeutic options to combat the ongoing pandemic. The company's dedication to addressing infectious diseases is reflected in its strategic development of these antiviral agents, which may play a crucial role in managing and mitigating the impact of viral infections.
Anixa’s vaccine development programs are equally ambitious. The company is working on a vaccine targeting triple-negative breast cancer, a particularly aggressive form of the disease with limited treatment options. Additionally, Anixa is developing a preventative vaccine against ovarian cancer, aimed at reducing the incidence of this challenging cancer type. These initiatives reflect the company's commitment to advancing cancer prevention and treatment through innovative vaccine technologies.
Founded as ITUS Corporation in 1982 and rebranded as Anixa Biosciences, Inc. in October 2018, the company is headquartered in San Jose, California. Anixa Biosciences continues to build on its legacy of innovation by exploring novel immunotherapy drugs and expanding its research capabilities to bring new solutions to the forefront of medical science.
|
